Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2010

View Archived Issues

Latrophilin-3 gene is linked to susceptibility to ADHD and response to stimulant medication

Scientists convert human fibroblasts directly to multipotent hematopoietic progenitors

New apoptosis-inducing molecules discovered

Tryptophan 5-hydroxylase 2 may be new target to treat depression

Fresolimumab improves symptoms of primary focal segmental glomerulosclerosis in phase I trial

CXR-1002 shows promising safety and antitumor activity in first-in-human trial in advanced cancer

Medgenics extends Factor VIII Biopump collaboration

Novel serotonin 5-HT6 receptor ligands identified by Abbott

MiStent drug-eluting coronary stent system advances into clinic

Banyu Pharma presents new antagonists of peptide P518 receptor

New inhibitors of dual specificity protein kinase TTK patented

New inhibitors of cell division protein kinase 4 claimed

Sanofi Pasteur begins phase II trial of ACAM-CDIFF vaccine

Worldwide rights to pegsiticase acquired by 3SBio from EnzymeRx

Transgenomic to purchase Clinical Data's diagnostic business

Merck & Co. reports phase III data on once-daily raltegravir in HIV-1

IntelGenx acquires rights to INT-0010 formulation of dronabinol

Hemispherx requests more to resubmit data to FDA for Ampligen NDA in chronic fatigue syndrome

FDA to review Spectrum Pharma's complete response regarding Fusilev sNDA

Lilly is recruiting healthy volunteers for first-in-human trial of LY-2979165

Nymox Pharma secures financing commitment

Eisai submits MAA for insomnia treatment SEP-190 in Japan

Thallion and LFB begin phase II trial of Shigamabs in STEC infections

Sucampo to update Japanese MAA for lubiprostone in chronic idiopathic constipation

Keryx's short-term phase III trial of Zerenex meets primary endpoints

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...